Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SIGLEC24P stands for “Sialic acid binding immunoglobulin-like lectin 24, pseudogene.” It is annotated as a pseudogene, meaning it is a nonfunctional segment of DNA related to the siglec (sialic acid-binding immunoglobulin-like lectin) gene family, but it does not encode a functional protein product in humans[7][9][1][5][3]. Pseudogenes often arise from duplication or retrotransposition events but have since accumulated mutations that prevent expression of a functional protein. Siglecs as a group are cell surface proteins involved in immune regulation, but pseudogene members like SIGLEC24P do not themselves participate in signaling or serve as drug targets[4][7][9]. There are no known biological functions, disease associations, interacting drugs, mechanisms of action, biomarker roles, or safety concerns specifically attributed to SIGLEC24P. The designation as a pseudogene means this entry should not be considered a therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sialic acid binding immunoglobulin-like lectin 24, pseudogene (SIGLEC24P).